pour la recherche uniquement
Réf. CatalogueS7914
| Lignées cellulaires | Type d'essai | Concentration | Temps d'incubation | Formulation | Description de l'activité | PMID |
|---|---|---|---|---|---|---|
| HCN | Function assay | Induction of NMDA receptor-mediated Ca2+ influx in rat HCN cells in presence of NMDA receptor antagonist MK801 | 18552832 | |||
| HCN | Function assay | 5 uM | Induction of L-type calcium channel/NMDA receptor-mediated Ca2+ influx in rat HCN cells at 5 uM by Fura-2 imaging analysis in presence of multiple of inhibitors | 18552832 | ||
| HCN | Function assay | 50 uM | 3 hrs | Induction of NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 3 hrs by RT-PCR analysis in presence of NMDA receptor antagonist MK801 | 18552832 | |
| HCN | Function assay | 25 uM | 4 days | Inhibition of gliogenesis differentiation in rat HCN cells at 25 uM after 4 days | 18552832 | |
| HCN | Function assay | 5 uM | Induction of L-type calcium channel/NMDA receptor-mediated Ca2+ influx in rat HCN cells at 5 uM by Fura-2 imaging analysis | 18552832 | ||
| HCN | Function assay | 5 uM | Induction of NMDA receptor-mediated Ca2+ influx in rat HCN cells at 5 uM by Fura-2 imaging analysis in presence of NMDA receptor antagonist MK801 | 18552832 | ||
| HCN | Function assay | 50 uM | 3 hrs | Induction of L-type calcium channel/NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 3 hrs by RT-PCR analysis in presence of multiple inhibitors | 18552832 | |
| HCN | Function assay | Induction of L-type calcium channel/NMDA receptor-mediated Ca2+ influx in rat HCN cells | 18552832 | |||
| HCN | Function assay | Induction of L-type calcium channel/NMDA receptor-mediated Ca2+ influx in rat HCN cells in presence multiple inhibitors | 18552832 | |||
| HCN | Function assay | 50 uM | 24 hrs | Induction of NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 24 hrs by RT-PCR analysis in presence of NMDA receptor antagonist MK801 | 18552832 | |
| HCN | Function assay | 50 uM | 24 hrs | Induction of NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 24 hrs by RT-PCR analysis in presence of NMDA receptor antagonist nifedipine | 18552832 | |
| HCN | Function assay | 50 uM | 24 hrs | Induction of L-type calcium channel/NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 24 hrs by RT-PCR analysis in presence of multiple inhibitors | 18552832 | |
| HCN | Function assay | 8 to 64 uM | 9 hrs | Induction of neurogenesis in undifferentiated rat HCN cells assessed as MAP2AB protein level at 8 to 64 uM after 9 hrs by protein blotting analysis | 18552832 | |
| HCN | Function assay | Induction of HDAC5 translocation in cytoplasm of rat HCN cells assessed as phosphorylated HDAC5 accumulation | 18552832 | |||
| HCN | Function assay | Induction of CAMK-mediated MREx3 activity in rat HCN cells by luciferase reporter gene assay in presence of 2.5 uM potassium channel inhibitor KN92 | 18552832 | |||
| HCN | Function assay | 8 to 64 uM | 9 hrs | Induction of neurogenesis in undifferentiated rat HCN cells assessed as GlR2/3 protein level at 8 to 64 uM after 9 hrs by protein blotting analysis | 18552832 | |
| HCN | Function assay | 6 hrs | Induction of HDAC5 phosphorylation in rat HCN cells after 6 hrs | 18552832 | ||
| HCN | Function assay | 24 hrs | Induction of HDAC5 phosphorylation in rat HCN cells after 24 hrs | 18552832 | ||
| HCN | Function assay | Induction of HDAC5 translocation in nucleus of rat HCN cells assessed as phosphorylated HDAC5 accumulation | 18552832 | |||
| HCN | Function assay | 5 uM | Induction of HDAC5 translocation in nucleus of rat HCN cells assessed as GFP-HDAC5 S258A S498A mutant fusion protein accumulation at 5 uM by fluorescence assay | 18552832 | ||
| HCN | Function assay | 50 uM | 3 hrs | Induction of NMDA receptor-mediated neuroD gene expression in rat HCN cells at 50 uM after 3 hrs by RT-PCR analysis in presence of NMDA receptor antagonist nifedipine | 18552832 | |
| HCN | Function assay | 20 uM | Induction of HDAC5 translocation in nucleus of rat HCN cells assessed as GFP-HDAC5 fusion protein accumulation at 20 uM by fluorescence assay | 18552832 | ||
| HCN | Function assay | Induction of CAMK-mediated MREx3 activity in rat HCN cells by luciferase reporter gene assay in presence of 200 nM PKC inhibitor Go6976 | 18552832 | |||
| HCN | Function assay | 24 hrs | Induction of L-type calcium channel-mediated neuroD gene expression in rat HCN cells after 24 hrs by luciferase reporter gene assay in presence of multiple inhibitors | 18552832 | ||
| HCN | Function assay | 24 hrs | Induction of L-type calcium channel-mediated neuroD gene expression in rat HCN cells after 24 hrs by luciferase reporter gene assay in presence of NMDA receptor antagonist MK801 | 18552832 | ||
| HCN | Function assay | 24 hrs | Induction of L-type calcium channel-mediated neuroD gene expression in rat HCN cells after 24 hrs by luciferase reporter gene assay in presence of NMDA receptor antagonist nifedipine | 18552832 | ||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 234.27 | Formule | C11H10N2O2S |
Stockage (À compter de la date de réception) | |
|---|---|---|---|---|---|
| N° CAS | 832115-62-5 | Télécharger le SDF | Stockage des solutions mères |
|
|
| Synonymes | N/A | Smiles | C1CC1NC(=O)C2=NOC(=C2)C3=CC=CS3 | ||
|
In vitro |
DMSO
: 47 mg/mL
(200.62 mM)
Ethanol : 12 mg/mL Water : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant l'expérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter d'abord s'il n'y a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter d'abord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant d'ajouter le solvant suivant.
2. Assurez-vous d'ajouter le(s) solvant(s) dans l'ordre. Vous devez vous assurer que la solution obtenue, lors de l'ajout précédent, est une solution claire avant de procéder à l'ajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| In vitro |
ISX-9 (Isoxazole 9) augmente le nombre de cellules et favorise la différenciation cellulaire dans les NSPC, tandis qu'il induit des dommages cellulaires dans les OPC. Dans les EPC en croissance, ce composé diminue la formation de tubes sans effet sur les EPC précoces.
|
|---|---|
| In vivo |
Chez la souris, ISX-9 (Isoxazole 9) (20 mg/kg, i.p.) traverse la BBB et augmente la prolifération des neuroblastes et la neurogenèse via des mécanismes spécifiques à Mef2 dans la SGZ hippocampique. Ce composé augmente également la différenciation et la complexité dendritique des neurones immatures et améliore la mémoire. Dans le MWM, il améliore la mémoire spatiale.
|
Références |
|